Reports FY24 revenue $89.1M, consensus $18.48M. “Our strong execution throughout 2024 and into 2025 has positioned ARS Pharma for sustained ...
JPMorgan upgraded Freeport-McMoRan (FCX) to Overweight from Neutral with a price target of $52, up from $48, which offers 30% implied upside.
Explore Cloudastructure stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for CSAI.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback